Cardlytics, Inc. (NASDAQ:CDLX) Given Average Recommendation of “Reduce” by Analysts

Cardlytics, Inc. (NASDAQ:CDLX) has received a consensus recommendation of “Reduce” from the seven brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating and six have given a hold rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $6.92.

Several research firms have recently commented on CDLX. Northland Securities cut Cardlytics from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $7.00 to $5.00 in a research note on Friday, August 16th. Bank of America lowered shares of Cardlytics from a “neutral” rating to an “underperform” rating and decreased their price objective for the stock from $4.00 to $3.50 in a report on Thursday, August 15th. Needham & Company LLC lowered shares of Cardlytics from a “buy” rating to a “hold” rating in a research note on Thursday, August 8th. Lake Street Capital downgraded Cardlytics from a “buy” rating to a “hold” rating and decreased their price target for the stock from $18.00 to $5.00 in a research note on Thursday, August 8th. Finally, Evercore ISI initiated coverage on Cardlytics in a research note on Friday, October 11th. They set an “in-line” rating and a $4.00 price objective on the stock.

Cardlytics Price Performance

CDLX opened at $3.88 on Tuesday. Cardlytics has a twelve month low of $2.89 and a twelve month high of $20.52. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 1.01. The firm has a market cap of $189.28 million, a price-to-earnings ratio of -0.88 and a beta of 1.67. The company has a fifty day simple moving average of $3.61 and a 200 day simple moving average of $7.25.

Cardlytics (NASDAQ:CDLX) last announced its earnings results on Wednesday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.12. The business had revenue of $69.64 million for the quarter, compared to analyst estimates of $75.39 million. Cardlytics had a negative return on equity of 17.96% and a negative net margin of 50.21%. The company’s revenue for the quarter was down 9.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.57) earnings per share. Equities research analysts expect that Cardlytics will post -1.72 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Scott A. Hill purchased 40,000 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The shares were acquired at an average price of $3.58 per share, with a total value of $143,200.00. Following the acquisition, the director now owns 40,000 shares in the company, valued at approximately $143,200. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Cardlytics news, CEO Amit Gupta sold 22,607 shares of the business’s stock in a transaction dated Thursday, October 24th. The shares were sold at an average price of $3.85, for a total transaction of $87,036.95. Following the completion of the transaction, the chief executive officer now directly owns 178,519 shares of the company’s stock, valued at $687,298.15. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Scott A. Hill purchased 40,000 shares of the company’s stock in a transaction on Monday, August 12th. The stock was purchased at an average price of $3.58 per share, for a total transaction of $143,200.00. Following the purchase, the director now directly owns 40,000 shares of the company’s stock, valued at $143,200. The disclosure for this purchase can be found here. Insiders have sold a total of 43,573 shares of company stock worth $151,612 over the last quarter. 4.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Cardlytics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CDLX. Check Capital Management Inc. CA increased its stake in Cardlytics by 83.1% during the 1st quarter. Check Capital Management Inc. CA now owns 42,475 shares of the company’s stock valued at $615,000 after buying an additional 19,275 shares during the period. Brooktree Capital Management raised its holdings in Cardlytics by 18.0% during the first quarter. Brooktree Capital Management now owns 138,970 shares of the company’s stock worth $2,014,000 after purchasing an additional 21,150 shares in the last quarter. ClariVest Asset Management LLC acquired a new stake in Cardlytics in the first quarter worth approximately $707,000. Susquehanna Fundamental Investments LLC lifted its holdings in shares of Cardlytics by 13.8% during the first quarter. Susquehanna Fundamental Investments LLC now owns 31,536 shares of the company’s stock valued at $457,000 after purchasing an additional 3,836 shares during the last quarter. Finally, Banco Santander S.A. acquired a new position in shares of Cardlytics in the 1st quarter valued at $199,000. 68.10% of the stock is owned by institutional investors.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.